Sixth Annual DCAT International Business Development Forum: Business Development in the Developing World: Case Studies in Sourcing Drugs for Global Pandemics Monday, March 10, 2008 Waldorf-Astoria Hotel, New York 1:15 pm- 4:15 pm Empire Room 4:15 pm- 5:15 pm Reception, Peacock Alley Private Dining Room
Registration for this program is now closed.  Walk-in attendees are welcome the day of the program.  Only credit card payments will be accepted on site.
The cancellation deadline for this program was Monday, March 3rd at 12:00pm EST.  In order to receive a full refund, you must have submitted your cancellation request prior to that date.
Reception Sponsored by:

DCAT is pleased to offer the sixth installment of its successful international business development program series.  This three-hour program is followed by a reception during which program participants are invited to meet the speakers and other attendees.  Both the program and reception are included in the registration fee.

This year’s forum will examine the issues involved in the supply chain for drugs that eradicate diseases such as HIV/AIDs, Malaria, and Tuberculosis.  This program will provide an overview of the current market, strategies for manufacturing and sourcing, qualification, technology, and the business potential for your company. Hear from key resources and industry leaders including The Boston Consulting Group, The World Health Organization, The Clinton Foundation, Merck, Lonza, and Matrix Laboratories. Each speaker will provide first-hand information on their role in the access-to-market business environment and provide you with the information necessary to succeed in this important sector of the industry.

Program topics will include:

Supply Chain Challenges and Opportunities in Developing World Diseases
Wendy Woods, Partner and Managing Director, The Boston Consulting Group
Much progress has been made in bringing new vaccines, drugs, diagnostics and other technologies to address diseases of the developing world.  This session will provide an overview of the challenges and opportunities the supply chain encounters in manufacturing for developing world diseases.

Facilitating Access to Safe, Effective, Quality Medicines through Prequalification
Adrian J. van Zyl, Ph.D., Technical Officer and Head of Inspection for the Prequalification Program, World Health Organization
The United Nations prequalification program facilitates access to priority essential medicines used in the treatment of HIV/AIDS, Tuberculosis and Malaria. This session will provide an overview of the World Health Organization’s (WHO) evaluation process including assessments and inspections of Active Pharmaceutical Ingredients and finished products, manufacturers, clinical research organizations and quality control laboratories. Learn what types of companies are participating in the prequalification program and why some fail and others succeed.

A New Approach to Expanding Access to Essential Medicines
Dai Ellis, Director, Drug Access Team, Clinton Foundation HIV/AIDS Initiative
Since 2002, the Clinton Foundation has been working with partners to expand access to antiretroviral drugs. These collective efforts have produced a ten-fold increase in the number of patients on AIDS treatment across the developing world in less than five years. This presentation will highlight the key insights that have emerged from this global effort, with a particular focus on the need to address demand and supply-side challenges in a coordinated way, as well as the opportunities to extend the approach to therapeutic areas beyond HIV/AIDS.

Challenges Faced in Balancing Social Objectives while Running the Antiretroviral Business
Yasir Y. Rawjee, Ph.D., Vice President, Business Development, Matrix Laboratories Ltd.
What are the challenges faced by R&D teams in devising cost-effective processes for more than fifteen antiretrovirals? Hear how Matrix’s association with organizations such as the Clinton Foundation and WHO, and pharmaceutical and generic companies have assisted them in the development of creative survival mechanisms for their API and Final Dosage Form business.

Sourcing and Product Access for the Developing World
Richard Spoor, Senior Vice President of Global Procurement, Merck & Co., Inc.  
As part of its "Plan to Win" strategy, Merck is aggressively pursuing value-added sourcing options for new products to broaden access for various pandemic diseases.  Learn more about Merck’s collaboration efforts with manufacturers in the developing world and public policy organizations to successfully establish viable supply chains to address this critical need for its products.

Technology and Manufacturing Excellence - Supporting Customers in Access-to-Medicine Markets
Uwe H. Boehlke, Ph.D., Chief Operarting Officer of Lonza Exclusive Synthesis
CMOs need to adopt leadership roles in technological advances, raw material / intermediate sourcing, operational efficiency and manufacturing know-how across all scales of production (pilot through commercial) in order to offer economical API supply. In this session learn how Lonza leverages its extensive experience and expertise to provide economical and secure API supply for companies wishing to establish innovative and life-saving drugs in ATM (access-to-medicine) markets.

This program was developed by the DCAT Education Committee.

Program Fees: Member Company - $129.00, Non-Member Company - $329.00. Registration fees include reception.

About the Speakers:

Uwe H. Boehlke, Ph.D., has been a Member of the Management Committee and Head of the Exclusive Synthesis business sector for Lonza since January 2007. Before joining Lonza he held various positions at SCHOTT AG, Mainz including Executive Vice President of the Home Tech global business unit from 2003-2006, and Vice President Global Research and Development from 1998-2003. Mr. Boehlke also held various positions at Fraunhofer-Gesellschaft, Munich and Institute of Production Technology, Aachen including chief engineer and member of the Institute Management from 1994-1996. Mr. Boehlke holds a degree and a Ph.D. in mechanical engineering as well as a degree in economics from the RWTH Aachen University.

Dai Ellis, is the Executive Vice President of Access Programs at the Clinton Foundation HIV/AIDS Initiative, where he leads the Foundation’s work on improving the marketplace for HIV/AIDS and malaria drugs and other essential commodities. Prior to his work at the Clinton Foundation, Mr. Ellis worked at McKinsey and Company serving clients in the pharmaceutical and biotechnology industries. He later joined the Center for Global Health and Economic Development at Columbia University under Dr. Jeffrey Sachs. His work at Columbia took him to Rwanda, where he worked as the advisor to the Director of the National AIDS Commission and helped to launch a national HIV/AIDS prevention and treatment program. While in Rwanda, he also co-founded Orphans of Rwanda, a nonprofit organization that provides university scholarships to orphans and other vulnerable youth. Mr. Ellis is a graduate of Yale Law School.

Yasir Y. Rawjee, is Vice President, Business Development with Matrix Laboratories Ltd. where he is responsible for handling the Active Pharmaceutical Ingredient business.  Previously, he was responsible for the Contract Research and Manufacturing division of Matrix forging new business relationships with small and large research-based global pharmaceutical companies. Prior to his career with Matrix, he worked on advanced projects, actively involved in technology transfers from R&D to commercial manufacturing, and was  involved with CMC regulatory filings for IND and NDA submissions to the US and European regulatory agencies.  Mr. Rawjee has a Ph.D. in Chemistry from Texas A&M University.

Richard Spoor is the Senior Vice President of Global Procurement and has the overall leadership responsibility for the Merck Global Procurement Organization. Mr. Spoor joined Merck in January 2005, as Vice President, Indirect Procurement, where he provided direction and leadership for the information services, media management, and corporate services procurement organizations. He became the Head of Global Procurement in May 2005.  He leads and manages a global team of over 400 professionals based in all regions of the world and is accountable for the company-wide total external spend of $7B across marketing, manufacturing and research operations. Mr. Spoor is a member of the Manufacturing Leadership Business Team (MLBT) at Merck & Co., Inc.

Prior to joining Merck, he was Regional Director, EMEA Operational Resource Sourcing at the Nokia Corporation, where he was responsible for sourcing across 25 countries. He spent several years in consultant and management positions with the QP Group, a leading-edge global procurement and supply consulting organization. He has a B.S. in Industrial Management from Nottingham Trent University.

Adrian J. van Zyl, Ph.D., is Technical Officer and Head of Inspection for the Prequalification Program of the World Health Organization, in Geneva, Switzerland.  In previous positions, he was Project Manager for the Prequalification Project of the United Nations, founding member and manager of Van Zyl GMP International consulting firm, Head of Inspection Division of South African Drug Regulatory Authority, Executive Director, Self-Medication Manufacturer’s Association of South Africa and President of the South African Association for Hospital and Institutional Pharmacists. He is a member of the World Health Organization’s (WHO) Panel of Experts and Member of WHO’s Expert Committee on Pharmaceutical Specifications and Preparations. He has done an extensive number of audits, inspections and training in various countries including India and China - to ensure the quality of medicines. Dr. van Zyl holds numerous degrees in Pharmacy including Bachelors, Masters and two Doctorates. 

Wendy Woods, is partner and managing director with The Boston Consulting Group.  She leads the firm’s efforts in global health and also works with pharmaceutical and biotechnology clients.  Currently based in the Boston, MA office, she has also worked on projects across Europe, Asia and Africa.  She leads the firm’s global public health efforts, working with foundations, public private partnerships and multilateral organizations.  Her work includes projects spanning the major developing world disease areas as well as vaccines, drugs and diagnostics.  Some specific examples of her work include assessing the market for malaria, TB and HIV vaccines with The Malaria Vaccine Initiative, BioVentures for Global Health, and The International AIDS Vaccine Initiative; re-designing the Roll Back Malaria Partnership; developing a commercialization strategy for The Institute for OneWorld Health; and developing a supply strategy for The Global Alliance for Vaccines and Immunization.  Wendy earned a Bachelor’s degree in economics from the University of Michigan and an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.